SREBF1 and metabolic dysfunction-associated steatohepatitis: To confirm the effect of BBR on intestinal FXR activation and FGF15 secretion, we detected the downstream lipogenesis genes in the liver, and found that BBR treatment significantly decreased the mRNA expression of sterol-regulatory element-binding protein 1 (SREBP1), acetyl-CoA carboxylase (ACC), fatty acid synthase (FASN), and stearoyl-CoA desaturase-1 (SCD1) in NASH mice (Figure 5A), suggesting the suppression of de novo lipogenesis upon BBR treatment.